SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
San West, Inc. (OTCBB: SNWT) $1.15. Announced Tuesday after market close its list of aggressive strategic initiatives aimed at dramatically increasing revenues for the short term fiscal year including the 3rd and 4th Quarter of 2009.
Strategic Initiatives Poised for the Next 12 months:
Increased focus on Buggy World Internet sector, where many competitors are not reaching target markets for buggy and off-road products.
With development of the new website, the company intends to promote itself online through sales, specials and a community forum
Pursuit of additional Buggy World dealership locations for increased market coverage and distribution territory as well as distributorships and industry alliances
Launch of marketing campaign through advertising, social media and increased industry event presence
Increased Buggy World distributorship of large industry brand names and companies such as recent distributorships with Fox Racing and Thor
Promotion of Buggy World repair shop and part sales which research shows is an industry niche as well as a revenue stream that increases during times of decreased expendable income
Added product inventory, such as Redline and Joyner, which appeals to wider range of sports enthusiasts
Key Milestones Achieved During Past 12 months:
Acquisition of Buggy World in October 2008, with reported revenue of $1.6 million for 2007
Merger with Human BioSystems, Inc. making San West a publicly traded company on the OTC Bulletin Board
Increased Buggy World part sales/repair shop income by 35%
Opening of new Buggy World location in Fallbrook, CA, expected to increase revenue by 30%
New Buggy World representation of top rated product lines such as Fox Racing and Thor
Redevelopment of Buggy World website with greater focus on online retail, off-road community and social portal
Awarded exclusive TrophyKart dealership for San Diego County
What They Do: San West designs, manufacturers, sells and repairs off-road buggies, and additionally provides aftermarket performance products and accessories for off-road buggies; products are sold via three divisions: at retail store locations; via the online store and; through its growing dealer network.
Note: StockTA shows SNWT's chart to be short-term bullish, medium and long-term very bullish.
GMXR (Nasdaq: GMXR) $15.17. Announced Tuesday after market close that Michael J. Rohleder, President and James A. Merrill, CFO will present at the IPAA OGIS San Francisco Conference on September 30, 2009 at 4:10 PM (PDT) in the Presidio Room of the Palace Hotel located at 2 New Montgomery Street, San Francisco, CA.
A copy of the IPAA presentation will be posted on the Company's website Tuesday, September 29, 2009. The Company's production for the three months ended September 30, 2009 is estimated to be 3.4 billion cubic feet equivalent ("Bcfe") of natural gas, which is in-line with previous Company guidance. The third quarter of 2009's estimated production is a 2% increase from 3.3 Bcfe in the second quarter of 2009 and a 4% decrease from 3.5 Bcfe in the third quarter of 2008. Since the second quarter of 2009, the Company has been operating a one rig Haynesville/Bossier Horizontal ("H/B Hz") drilling program and has been able to maintain stable production with a 50% reduction in CAPEX.
What They Do: GMXR is a 'Pure Play', E & P Company with one of the most leveraged Haynesville / Bossier Horizontal Shale Operations in East Texas.
The Medicines Company (Nasdaq: MDCO) $11.28. Announced after market close Tuesday that it has entered into a license agreement with Eagle Pharmaceuticals, Inc. (Eagle) under which The Medicines Company will have rights in the United States and Canada to a ready-to-use formulation of Argatroban, which is currently under review by the U.S. Food and Drug Administration (FDA).
"The Medicines Company is pleased to announce our agreement with Eagle," said Clive Meanwell, M.D., Chairman and Chief Executive Officer of The Medicines Company. "Argatroban is a valuable therapeutic option for critical care patients, with U.S. sales in the currently marketed formulation of about $140 million in 2008. We believe we can capture a portion of that market by providing this innovative formulation, which has the potential to address the needs of our customers by providing an economically favorable product in an indication for which Angiomax is not approved."
What They Do: The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com.. Actual results may differ materially from the Company's expectations and estimates. The information provided in this report is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
